Want to see AIM full AI Analyst Report?
AIM ImmunoTech (AIM) Stock Statistics & Valuation Metrics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $6.18M. The enterprise value is -$1.18M.
- Market Cap
- $6.18M
- Enterprise Value
- -$1.18M
Share Statistics
AIM ImmunoTech has 39,894,844 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 39,894,844
- Owned by Insiders
- 0.60%
- Owned by Institutions
- 0.13%
Financial Efficiency
AIM ImmunoTech’s return on equity (ROE) is 1.43 and return on invested capital (ROIC) is -313.55%.
- Return on Equity (ROE)
- 1.43
- Return on Assets (ROA)
- -2.41
- Return on Invested Capital (ROIC)
- -313.55%
- Return on Capital Employed (ROCE)
- 23.81
- Revenue Per Employee
- 4,631.579
- Profits Per Employee
- -734.63K
- Employee Count
- 19
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of AIM ImmunoTech is -0.04. AIM ImmunoTech’s PEG ratio is -0.00.
- PE Ratio
- -0.04
- PS Ratio
- 65.09
- PB Ratio
- 0.34
- Price to FCF
- -0.86
- Price to Operating Cash Flow
- -0.38
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of 88.00K and earned -13.96M in profits. Earnings per share was -8.62.
- Revenue
- 88.00K
- Gross Profit
- -250.00K
- Operating Income
- -10.53M
- Pretax Income
- -13.96M
- Net Income
- -13.96M
- EBITDA
- -12.94M
- Earnings Per Share (EPS)
- -8.62
Cash Flow
In the last 12 months, operating cash flow was -7.07M and capital expenditures -95,000, giving a free cash flow of -7.16M billion.
- Operating Cash Flow
- -7.07M
- Free Cash Flow
- -7.16M
- Free Cash Flow per Share
- -0.42
Dividends & Yields
AIM ImmunoTech pays an annual dividend of $0.27, resulting in a dividend yield of ―
- Dividend Per Share
- $0.27
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -115.79%
- Earnings Yield
- -537.80%
Stock Price Statistics
- Beta
- 0.97
- 52-Week Price Change
- -90.71%
- 50-Day Moving Average
- 0.19
- 200-Day Moving Average
- 0.45
- Relative Strength Index (RSI)
- 43.56
- Average Volume (3m)
- 4.44M
Important Dates
AIM ImmunoTech upcoming earnings date is Aug 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Aug 17, 2027
- Ex-Dividend Date
- ―
Financial Position
AIM ImmunoTech as a current ratio of 0.53, with Debt / Equity ratio of -50.05%
- Current Ratio
- 0.53
- Quick Ratio
- 0.53
- Debt to Market Cap
- 2.58
- Net Debt to EBITDA
- -0.31
- Interest Coverage Ratio
- -12.96
Taxes
In the past 12 months, AIM ImmunoTech has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
AIM ImmunoTech EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.03.
- EV to Sales
- 2.15
- EV to EBITDA
- -0.02
- EV to Free Cash Flow
- -0.03
- EV to Operating Cash Flow
- -0.03
Balance Sheet
AIM ImmunoTech has $9.96M in cash and marketable securities with $3.92M in debt, giving a net cash position of $6.04M billion.
- Cash & Marketable Securities
- $9.96M
- Total Debt
- $3.92M
- Net Cash
- $6.04M
- Net Cash Per Share
- $0.15
- Tangible Book Value Per Share
- $0.35
Margins
Gross margin is -125.26%, with operating margin of -11637.89%, and net profit margin of -15021.05%.
- Gross Margin
- -125.26%
- Operating Margin
- -11637.89%
- Pretax Margin
- -15021.05%
- Net Profit Margin
- -15021.05%
- EBITDA Margin
- -13120.00%
- EBIT Margin
- -13823.16%
Analyst Forecast
The average price target for AIM ImmunoTech is $4.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $4.25
- Price Target Upside
- 2641.94% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -21.49%
- EPS Growth Forecast
- 84.62%
Scores
- Smart Score
- ―
- AI Score
- 41
